Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:25 PM
Ignite Modification Date:
2025-12-24 @ 2:25 PM
NCT ID:
NCT00684359
Eligibility Criteria:
Inclusion Criteria:
* Patients, male or female, \> 18 years of age,
* Patients who are scheduled for an elective PCI with a drug eluting stent
* Patients willing to return for all required follow up visits.
* Patients live/work within a 60 mile radius of the Washington Hospital Center.
Exclusion Criteria:
* Patient has experienced an acute myocardial infarction within the preceding 48 hours of the subsequent angioplasty.
* Unprotected left main coronary disease with \>50% stenosis;
* Patients with renal failure requiring dialysis;
* Patients with a documented ejection fraction \< 30 percent at the time of subsequent PCI;
* Patient with a life expectancy less than 12 months or malignancy.
* Known allergies to aspirin or clopidogrel bisulfate (PlavixR) and that cannot be medically managed;
* Planned surgery or other indication for requiring the cessation of clopidogrel within 12 months of PCI;
* Any significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study.
* Patients with known history of bleeding diathesis;
* Prothrombin time \>1.5 times control; coumadin therapy
* Platelet count \<100 000/mm3;
* Hematocrit \<25%;
* Creatinine \>4.0 mg/dL;
* Thienopyridine use within 5 days of enrollment
* Glycoprotein (GP) IIb/IIIa use within 8 hours of enrollment or any indication were the operator will require GP IIb/IIIa inhibitor use during the hospitalization.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00684359
Study Brief:
Protocol Section:
NCT00684359